Baseline characteristics by STPR group
| Rapid (n=272) | Intermediate (n=277) | Slow (n=274) | p Value | |
|---|---|---|---|---|
| Mean age at first visit±SD, years | 50.8±13.6 | 48.4±13.2 | 48.4±13.6 | 0.13 |
| Female | 76% | 75% | 75% | 0.91 |
| Race | ||||
| Caucasian | 91% | 90% | 88% | 0.55 |
| African American | 5% | 4% | 7% | 0.30 |
| Other | 4% | 6% | 5% | 0.57 |
| Median total skin score (IQR) | 33.0 (25.0, 40.0) | 27.0 (20.0, 36.0) | 17.0 (12.0, 23.0) | <0.0001 |
| Median years from onset of patient-reported skin thickening (IQR) | 0.5 (0.4, 0.6) | 0.8 (0.6, 1.0) | 1.1 (0.9, 1.6) | <0.0001 |
| Autoantibody | ||||
| Anti-RNA polymerase III | 55% | 52% | 31% | <0.0001 |
| Anti-topoisomerase I | 22% | 22% | 31% | 0.01 |
| Anti-U1RNP | 2% | 2% | 1% | 0.15 |
| Anti-U3RNP | 2% | 3% | 5% | 0.60 |
| Anti-U11/U12RNP | 1% | 1% | 1% | 0.87 |
| Anti-Ku | 0% | 2% | 2% | 0.24 |
| Anti-centromere | 0% | 1% | 1% | 0.38 |
| Anti-PM-Scl | 0% | 0% | 1% | 0.05 |
| Anti-Th/To | 0.1% | 0% | 0% | 0.36 |
| Organ involvement at first visit | ||||
| Renal | 12% | 9% | 9% | 0.48 |
| Cardiac | 12% | 14% | 12% | 0.83 |
| Pulmonary | 29% | 27% | 29% | 0.80 |
| Gastrointestinal | 40% | 36% | 37% | 0.57 |
IQR, interquartile range; SPTR, skin thickness progression rate.